Moteur de recherche d’entreprises européennes
Financement de l’UE (11 M €) : Impact de l’exposome sur l’évolution des maladies pulmonaires Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Impact de l’exposome sur l’évolution des maladies pulmonaires
Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are two very debilitating non-communicable diseases that are of particular interest to consider in parallel in a human exposome study. Their roots are opposite: COPD is currently considered to be mainly related to the external exposome, while factors outside of the exposome play a major role in CF. However, COPD and CF share common characteristics such as high phenotypic variability of unknown origin, which prevents good therapeutic efficacy. It is therefore clear that the overall picture must be supplemented by taking into account additional components of the exposome than those currently considered in COPD and CF. Thus, the overall objective of the REMEDIA project is to extend the understanding of the contribution of the exposome, taken as a complex set of different components, to COPD and CF diseases. We will exploit data from existing cohorts and population registries in order to create a unified global database gathering phenotype and exposome information; we will develop a flexible individual sensor device combining environmental and biomarker toolkits; and use a versatile atmospheric simulation chamber to simulate the health effects of complex exposomes. We will use machine learning supervised analyses and causal inference models to identify relevant risk factors; and econometric and cost-effectiveness models to assess the costs, performance and cost-effectiveness of a selection of prevention strategies. The results will be used to develop guidelines to better predict disease risks and constitute the elements of the REMEDIA toolbox (global unified database, sensor device, versatile atmospheric simulation chamber, machine learning supervised analyses, causal inference model, Pan-European multi-criteria risk assessment tool, econometric models, cost-effectiveness models, new guidelines and recommendations). Deciphering the impact of environmental components throughout life on the phenotypic variability of COPD and CF could represent a major breakthrough in reducing morbidity and mortality associated with these two non-curable diseases and would lead to the identification of modifiable risk factors on which preventive action could be implemented. REMEDIA will be part of the European Human Exposome Network established between the 9 projects funded within the Human Exposome programme call H2020-SC1-BHC-2018-2020.
| Cambridge Epigenetix Ltd. | 0,00 € |
| Centre Hospitalier Intercommunal de Creteil | 296 715 € |
| Centre National de la Recherche Scientifique CNRS | 0,00 € |
| DATA MINING INTERNATIONAL SA | 776 913 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 1 638 257 € |
| Idryma Technologias Kai Erevnas | 462 151 € |
| Inserm Transfert SA | 442 165 € |
| Institut National de la Sante et de la Recherche Medicale | 2 978 756 € |
| Kaduce+ | 331 125 € |
| Katholieke Universiteit Leuven | 672 477 € |
| Kraeftens Bekaempelse | 277 111 € |
| LAURENT NIDDAM EUROPAI KOZOSSEGI JOGASZ IRODA | 156,40 € |
| LIPOTYPE | 730 698 € |
| Universite Paris Cite | 1 853 955 € |
| Universite Paris XII Val de Marne | 0,00 € |
| Universitetet I Tromsoe - Norges Arktiske Universitet | 345 356 € |
| WELLSPRING kft. | 207 187 € |
https://cordis.europa.eu/project/id/874753
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.